17-Hydroxyprogesterone (17-OHP) is a steroid hormone your body produces as an intermediate step on the way to making cortisol and sex hormones. Most people encounter the term for the first time on a newborn screening report, where elevated 17-OHP is the primary flag for congenital adrenal hyperplasia (CAH), a condition that can become life-threatening within the first weeks of life. But this hormone also figures into the diagnosis of adult hormonal disorders, the monitoring of CAH treatment, and even reproductive medicine.
Where 17-OHP Fits in Hormone Production
Your adrenal glands, small organs sitting on top of each kidney, produce 17-OHP as part of the assembly line that manufactures cortisol, your body’s main stress hormone. An enzyme called 21-hydroxylase normally converts 17-OHP into the next product down the line. When 21-hydroxylase is missing or impaired, 17-OHP accumulates in the blood, like cars backing up behind a closed highway lane. That buildup is the hallmark of the most common form of CAH.
The accumulated 17-OHP doesn’t just sit there. It gets shunted into alternative pathways that produce androgens. Increased activity of the enzyme CYP17A1, seen in various endocrine disorders, drives the production of both elevated 17-OHP and elevated androgens.{1PubMed Central. CYP17A1 exhibits 17αhydroxylase/17,20-lyase activity towards 11β-hydroxyprogesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway} This androgen overflow explains many of CAH’s clinical features, from ambiguous genitalia in newborn girls to early puberty in children.
A separate “backdoor” biosynthetic pathway can convert excess 17-OHP into dihydrotestosterone, a potent androgen, without going through testosterone as an intermediate. This route helps explain why female fetuses with certain CAH variants develop virilized genitalia even when their testosterone levels aren’t dramatically high.2PubMed Central. Alternative pathway androgen biosynthesis and human fetal female virilization
Newborn Screening for CAH
Nearly every baby born in developed countries has a tiny blood sample taken from a heel prick within the first few days of life. One of the things that sample checks for is 17-OHP. If levels are high, the baby could have CAH. The majority of CAH cases are caused by 21-hydroxylase deficiency, and the most severe “salt-wasting” form can trigger a life-threatening adrenal crisis in the first two weeks of life if cortisol and aldosterone deficiencies go unrecognized.3PubMed Central. Congenital adrenal hyperplasia: an update in children
The initial test uses an immunoassay, an antibody-based measurement, on the dried blood spot. The trouble is that traditional immunoassays aren’t very specific for 17-OHP. Other steroids that look chemically similar can cross-react with the antibodies and produce falsely high readings.4PubMed. Liquid chromatography-tandem mass spectrometry analysis of 17-hydroxyprogesterone in dried blood spots revealed matrix effect on immunoassay The result is an unusually high callback rate that puts many families through days of unnecessary anxiety.
Why False Positives Are So Common
The false-positive rate in newborn CAH screening is among the highest of any condition on the standard panel, and several factors compound the problem.
Premature and low-birth-weight babies are the biggest source of false alarms. Gestational age and birth weight are the strongest contributors to variation in 17-OHP concentration, and babies at the extremes of birth weight produce significantly more positive screening results.5PubMed Central. Replication of clinical associations with 17-hydroxyprogesterone in preterm newborns In New York State’s screening program, more than 60% of referred cases that turned out to have no disease were low-birth-weight infants. The positive predictive value for full-term babies was around 13%, but for preterm babies it fell to just 1%.6Molecular Genetics and Metabolism Reports. Newborn screening for congenital adrenal hyperplasia in New York State
Sample timing matters too: specimens collected on the day of birth generate more false positives. And in some cases, medications the mother took during pregnancy interfere. Maternal use of inhaled corticosteroids, for example, has been documented as a potential cause of missed CAH diagnosis because the exogenous steroid can suppress the baby’s own 17-OHP production.7PubMed Central. Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot That scenario is the opposite problem: a false negative rather than a false positive, but it stems from the same lack of analytical specificity.
The solution screening programs have been moving toward is a two-tier approach. The initial immunoassay casts a wide net, and any positive result then gets re-analyzed using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), a technology that can distinguish 17-OHP from structurally similar molecules far more precisely. In New Zealand, adding LC-MS/MS as a second-tier test cut false positives from 172 to 40 over two years and raised the positive predictive value from under 2% to over 11%.8PubMed Central. Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand A Chinese screening program using a similar two-tier strategy reduced false positives by about 89% and pushed the positive predictive value up to 26%.9PubMed. Steroid profile in dried blood spots by liquid chromatography tandem mass spectrometry: Application to newborn screening for congenital adrenal hyperplasia in China
Classic Versus Non-Classic CAH
Not everyone with a 21-hydroxylase deficiency has the severe form of CAH. The “classic” form shows up at birth: cortisol production is severely impaired, 17-OHP levels are dramatically elevated, and about three-quarters of affected babies also lose salt because aldosterone production is compromised. The “non-classic” form, sometimes called late-onset CAH, involves a milder enzyme deficiency. These individuals produce enough cortisol to avoid a crisis, but their androgen levels are modestly elevated.
People with non-classic CAH often go undiagnosed until adolescence or adulthood, when symptoms bring them to a doctor. Undiagnosed non-classic CAH can contribute to infertility, recurrent miscarriages, irregular periods, excess body hair, persistent acne, and other problems.10PubMed. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome The condition is relatively common: estimates suggest it may affect roughly 1 in 200 to 1 in 1,000 people in the general population, depending on ethnic background, making it one of the more frequent autosomal recessive conditions.
Diagnosing Non-Classic CAH
A morning blood draw measuring baseline 17-OHP is the usual first step for anyone suspected of having non-classic CAH. If levels are elevated, the gold-standard confirmation is the ACTH stimulation test: a synthetic form of the pituitary hormone ACTH is injected, and 17-OHP is measured again 30 to 60 minutes later. A healthy adrenal gland responds with a modest rise; in someone with 21-hydroxylase deficiency, 17-OHP climbs sharply because the enzyme bottleneck becomes more obvious when the adrenal glands are pushed to work harder.11PubMed. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome
The exact cutoff values used to interpret these tests depend heavily on the assay method, and this is where things get tricky. Older immunoassay-based measurements can produce false-positive diagnoses of non-classic CAH. One study found that using a stimulated 17-OHP threshold of 30 nmol/L by immunoassay led to false positives, and recommended definitive diagnosis be confirmed by urine steroid profiling or genetic testing.12PubMed. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis
Newer LC-MS/MS methods improve accuracy. Research using these more precise assays found that a baseline 17-OHP cutoff around 6 nmol/L works well as a screening threshold, with optimal diagnostic cutoffs for stimulated 17-OHP around 15 nmol/L when measured by mass spectrometry.13Journal of the Endocrine Society. Screening for Nonclassic Congenital Adrenal Hyperplasia in the Era of Liquid Chromatography-Tandem Mass Spectrometry A large Italian study of children with early pubic hair development found that an ACTH-stimulated 17-OHP cutoff of 42 nmol/L achieved roughly 91% sensitivity and 100% specificity for distinguishing non-classic CAH from other causes of premature pubarche.14PubMed. Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche
The practical implication: if you’re told you “might have CAH” based on a single blood test, the method used to measure 17-OHP matters a great deal. Genetic testing for mutations in the CYP21A2 gene can provide a definitive answer when hormone measurements leave uncertainty.
Telling Apart PCOS and Non-Classic CAH
Polycystic ovary syndrome (PCOS) and non-classic CAH share many visible symptoms: acne, excess facial or body hair, irregular menstrual cycles, and difficulty getting pregnant. Because of this overlap, women are sometimes told they have PCOS when they actually have non-classic CAH, or vice versa. Some studies suggest that a measurable fraction of women initially diagnosed with PCOS turn out to carry 21-hydroxylase mutations on closer testing.
A 17-OHP measurement is the recommended screening tool to distinguish the two conditions, but baseline levels can overlap between the groups, which is why an ACTH stimulation test is often needed to separate them clearly.15PubMed Central. Polycystic Ovary Syndrome and NC-CAH: Distinct Characteristics and Common Findings. A Systematic Review The distinction matters because the treatment strategies differ. PCOS is typically managed with hormonal contraceptives and insulin-sensitizing medications, while non-classic CAH may respond better to low-dose glucocorticoid therapy that quiets the overactive adrenal gland. Getting the wrong label can mean years on a treatment that never quite works.
How 17-OHP Levels Shift Through the Month and During Pregnancy
For anyone who menstruates, 17-OHP levels are not constant. The ovaries produce 17-OHP in addition to the adrenal glands, and ovarian output rises after ovulation. Levels during the luteal phase (the second half of the cycle) are roughly double those during the follicular phase (the first half). One study measuring salivary 17-OHP found follicular-phase averages around 20 pg/mL compared to about 46 pg/mL in the luteal phase, with a peak between cycle days 16 and 18 followed by a steady decline back to follicular levels by day 28.16Fertility and Sterility. Salivary progesterone, 17α-hydroxyprogesterone, and cortisol during the normal menstrual cycle
17-OHP also follows a circadian rhythm that changes across the cycle. In the early follicular phase, levels rise and fall with cortisol over the course of the day, peaking in the early morning. As ovarian production ramps up after ovulation, the larger ovarian contribution masks this daily rhythm entirely.17Contraception. Studies on ovarian and adrenal steroids at different phases of the menstrual cycle: II. A comparative assessment of the circadian variation in steroid and lutropin levels during the follicular, periovulatory and luteal phases This is why clinicians typically ask patients to have their blood drawn early in the morning during the follicular phase. At that point in the cycle, adrenal output dominates and circadian confounders are minimal, giving the clearest read on whether baseline 17-OHP is truly elevated.
During early pregnancy, the corpus luteum (the structure left behind in the ovary after an egg is released) is the main source of 17-OHP. As the pregnancy progresses and the placenta takes over progesterone production, 17-OHP levels decline because the placenta does not produce 17-OHP the way the corpus luteum does. The declining trajectory of 17-OHP relative to rising total progesterone serves as a useful marker of the transition from luteal to placental hormone support.18Global Library of Women’s Medicine. Corpus Luteum
Monitoring Treatment in People with CAH
For people living with classic CAH, lifelong glucocorticoid replacement therapy (usually hydrocortisone in children) is necessary to supply the cortisol the body can’t make on its own. Getting the dose right is a constant balancing act. Too little glucocorticoid allows 17-OHP and androgens to climb, causing unwanted masculinizing effects and, in children, accelerated bone maturation that can limit final adult height. Too much suppresses growth and brings the familiar side effects of excess steroid exposure.
Doctors track 17-OHP levels to gauge how well treatment is working, but the hormone’s pronounced daily rhythm complicates interpretation. The maximum suppressive effect of a morning hydrocortisone dose occurs about three hours after it’s taken, and an evening dose keeps adrenal hormones suppressed until roughly 5 a.m. the next morning.19PubMed Central. Duration of suppression of adrenal steroids after glucocorticoid administration Timing blood draws relative to medication doses is therefore essential. A sample drawn right before the morning dose will show 17-OHP at its highest, while one drawn three hours later will reflect the peak suppressive effect.
Poor hormonal control, reflected in persistently high 17-OHP and androstenedione levels, has been linked to the development of testicular adrenal rest tumors (TARTs) in males with CAH. These are benign growths of adrenal-like tissue that develop in the testes, found in a substantial proportion of men with classic CAH. Roughly 58% of patients with these tumors have been in poor hormonal control, though the tumors occasionally appear even in well-managed patients.20Journal of Clinical Research in Pediatric Endocrinology. Long-term Complications and Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia Routine ultrasound screening for TARTs is recommended for adolescent and adult males with CAH.
The Pharmaceutical Version and Its Rise and Fall
There is a synthetic drug called 17-alpha hydroxyprogesterone caproate (often abbreviated 17P and formerly sold under the brand name Makena) that is chemically related to natural 17-OHP but functions as a long-acting progestational agent. For years it was used to reduce the risk of recurrent preterm birth. A landmark 2003 trial found that weekly injections of 17P reduced delivery before 37 weeks from about 55% in the placebo group to about 36% in the treatment group, a roughly one-third reduction in risk. Babies whose mothers received the drug also had lower rates of serious neonatal complications like brain bleeds and necrotizing enterocolitis.21PubMed. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate
Based on that trial, the FDA granted accelerated approval to Makena in 2011. A much larger confirmatory trial called PROLONG, however, failed to replicate the benefit: 17P showed no meaningful reduction in preterm birth or improvement in neonatal outcomes compared with placebo. In 2023, the FDA withdrew approval of Makena, concluding that the confirmatory evidence did not support the drug’s continued availability.22PubMed Central. The end is where we start from: withdrawal of 17-alpha hydroxyprogesterone caproate to prevent recurrent preterm birth The episode marked one of the few times the FDA has used its authority to pull a drug from the market after an accelerated approval. For patients, it’s a reminder that promising early trial results sometimes do not hold up in larger, more diverse studies.
Why the Measurement Method Keeps Coming Up
A thread running through nearly every clinical use of 17-OHP is that the method of measurement can change the answer you get. Traditional immunoassays are cheap, fast, and widely available, but they suffer from cross-reactivity with other steroids that share a similar chemical backbone.23PubMed. Clinical determination of 17-hydroxyprogesterone in serum by LC-MS/MS: comparison to Coat-A-Count RIA method This cross-reactivity inflates newborn screening false-positive rates, muddles the adult diagnosis of non-classic CAH, and can lead to over- or under-treatment in people already known to have the condition.
LC-MS/MS has become the reference standard in laboratories that have access to it, but the equipment is expensive and requires trained technicians, so immunoassays remain the workhorse in many clinical settings. If a 17-OHP result leads to a surprising or concerning diagnosis, it is worth asking whether the measurement was done by immunoassay or by mass spectrometry. A single elevated immunoassay result, especially one near the diagnostic cutoff, is not a definitive answer. Confirmatory testing with a more specific method, or genetic analysis of the CYP21A2 gene, can prevent unnecessary worry and misdirected treatment.